ArticleNuclear medicine communications2025
Diagnostic value of baseline 18 F-FDG PET/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin's lymphoma.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of standardized uptake value and standardized uptake lean body mass metrics inQuantitative imaging in medicine and surgery · 2025Article
- Unraveling the complexity of follicular lymphoma: insights and innovations.American journal of cancer research · 2024Review
- Analysis of 18 F-FDG PET/CT Imaging Features of Nodal Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.Journal of computer assisted tomographyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to investigate the diagnostic value of baseline F18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) parameters and peripheral blood inflammatory markers in aggressive lymphoma of non-Hodgkin lymphoma (NHL) and the correlation between peripheral blood inflammatory markers and maximum standardized uptake value (SUV max ). PATIENTS AND
methodsWe conducted a retrospective analysis including 121 patients with NHL. Patients were divided into aggressive lymphoma group and indolent lymphoma group. Mann-Whitney U test, chi-square test and multivariate stepwise logistic regression were used to analyse. Subsequently, receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic performance. Additionally, Spearman correlation analysis was utilized to explore the correlation between peripheral blood inflammatory markers and SUV max .
resultsLeptin mass criterion uptake value (SUL) max , SUV max , SUV avg , SUV peak , focal SUV max /liver SUV max , focal SUV max / mediastinal SUV max , SUL avg , SUL peak , systemic immune-inflammation (SII), neutrophil ratio, total lesion glycolysis (TLG), neutrophils versus lymphocyte ratio (NLR), plateletto-lymphocyte ratio (PLR), lactate dehydrogenase (LDH) and lymphocyle ratio between two groups were statistically significant ( P < 0.05). SUV max was an independent influencing factor, and the area under the ROC curve was 0.862. There was a positive correlation between the PLR and SUV max ( r = 0.239; P = 0.008).
conclusionPET/CT parameters and peripheral blood inflammatory markers have certain value in the diagnosis of aggressive lymphoma in NHL, among which SUV max is an independent influencing marker and is positively correlated with PLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.